> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Drug Use-related Software Labeling Guide
- URL: https://www.fdaweb.com/drug-use-related-software-labeling-guide/
- Published: 2023-09-18T12:00:00.000Z
- Updated: 2026-09-14T18:56:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155347

FDA has released a [draft guidance](https://www.fda.gov/media/172165/download?ref=fdaweb.com) entitled “Regulatory Considerations for Prescription Drug Use-Related Software.” The document describes the agency’s application of its drug labeling authorities to certain software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug or a drug-device combination that is regulated by CDER/CBER. 

According to the guidance, a pharmaceutical drug use-related software generally includes software that: “(**1**) is disseminated by or on behalf of a drug sponsor and (**2**) produces an end-user output that supplements, explains, or is otherwise textually related to one or more of the sponsor’s drug products. A software function is any distinct purpose of the software, and end-user output is any material (content) that the prescription drug use-related software presents to the end user (a patient, caregiver, or health care practitioner).” FDA says it considers end-user output a type of prescription drug labeling. 

“For prescription drug use-related software, sponsors may propose including information specifying that use of the prescription drug use-related software with the product results in a meaningful improvement in a clinical outcome as compared to use of the product without the prescription drug use-related software (demonstrated by one or more adequate and well-controlled studies),” FDA says. “For example, the evidence may demonstrate that a combination product with device-connected prescription drug use-related software (e.g., a dose-tracking app that relies on data on drug use directly transferred from a device constituent part within the product) leads to a meaningful change in a clinical outcome or validated surrogate endpoint compared to using the combination product without the device-connected prescription drug use-related software.” The agency recommends that such information be included in the Prescribing Information’s Clinical Studies section.